MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Kisspeptin Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Kisspeptin is the protein product of the KISS1 gene, processed into bioactive C-terminal fragments (kisspeptin-54, -14, -13, and -10) that act as obligate upstream regulators of the gonadotropin-releasing hormone (GnRH) pulse generator in the arcuate and rostral periventricular hypothalamus through binding the G-protein-coupled receptor KISS1R (formerly GPR54). Loss-of-function KISS1R mutations cause normosmic isolated hypogonadotropic hypogonadism, establishing kisspeptin as essential for pubertal initiation and reproductive function in both sexes. Researchers study it for hypothalamic amenorrhea, hypoactive sexual desire disorder, fertility induction, polycystic ovary syndrome neuroendocrine characterization, and as a safer ovulation trigger in IVF where it avoids the ovarian hyperstimulation syndrome risk seen with hCG. Foundational human physiology and reproductive endocrinology work has been published by Dhillo, Skorupskaite, and colleagues at Imperial College London (PMID 28076081, PMID 28739637).
Reconstitute: Add 3 mL bacteriostatic water → 3.33 mg/mL concentration.
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL = 0.0333 mg (33 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Plasma half-life: Approximately 28 minutes for kisspeptin-54 and roughly 4 minutes for kisspeptin-10 after intravenous administration, requiring infusion or frequent bolus dosing for sustained LH pulse stimulation.
Onset: LH rise is detectable within 15 to 30 minutes of subcutaneous or intravenous kisspeptin-54 administration in healthy volunteers, with peak LH at 60 to 90 minutes.
Regulatory status: Not approved by FDA or EMA. Investigational in fertility, neuroendocrinology, and sexual function trials, with phase 2 work ongoing for IVF trigger and HSDD applications.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[19].
Interactive Kisspeptin Syringe Calculator
Currently visualizing the 10 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 10mg dry powder in 3mL water yields 3.33 mg/mL. To evaluate a 250mcg dose, pull to 7.5 units (8 syringe ticks).
U-100 Syringe Representation
7.5 Units (8 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 3 units (0.03 mL) |
| Weeks 3–8 (or 3–12) | 200 mcg | 6 units (0.06 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 10 mg vial.
Peptide Vials (Kisspeptin, 10 mg each):
- check8 weeks ≈ 1 vial
- check12 weeks ≈ 2 vials
- check16 weeks ≈ 3 vials
Insulin Syringes (U‑100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- check8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
- check12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- check16 weeks (3 vials): 9 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- check12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- check16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Mechanism of Action (MOA)
The KISS1 gene encodes a 145-amino-acid precursor that is processed into kisspeptin-54 and shorter biologically active fragments, all of which share a C-terminal arginine-phenylalanine-amide motif required for KISS1R binding [1][2]. KISS1R is a Gq-coupled receptor expressed densely on GnRH neuron cell bodies in the medial preoptic area; receptor activation increases intracellular calcium, depolarizes GnRH neurons, and triggers the synchronized release of GnRH into the hypophyseal portal circulation [3]. Two anatomically distinct kisspeptin populations modulate this circuit: arcuate (ARC) KNDy neurons generate the pulsatile baseline that drives basal LH and FSH secretion, while rostral periventricular (RP3V) neurons mediate the estradiol-positive feedback surge required for ovulation [2]. Sex steroid feedback acts oppositely on the two populations: estradiol inhibits ARC kisspeptin expression but stimulates RP3V neurons, a wiring pattern that explains both negative and positive feedback in the same hormonal milieu. The half-life of intravenous kisspeptin-10 is approximately 4 minutes; kisspeptin-54 has a half-life of approximately 28 minutes, making it the preferred clinical tool for sustained stimulation [5]. After subcutaneous injection of 9.6 nmol/kg kisspeptin-54 in healthy women, plasma LH rises within 15 to 30 minutes and peaks at approximately 60 to 90 minutes, with the magnitude depending on the menstrual cycle phase: smallest in the follicular phase, largest in the preovulatory phase [4]. Clinical applications under active investigation include kisspeptin-54 as a substitute for human chorionic gonadotropin (hCG) trigger in IVF cycles, where it produces a more physiological LH/FSH surge and dramatically reduces the risk of ovarian hyperstimulation syndrome (OHSS) [6][7]. In hypothalamic amenorrhea, kisspeptin restores LH pulsatility and supports follicle development. In men, kisspeptin-10 boluses increase LH pulse frequency and amplitude, raising testosterone within 2 to 4 hours [8]. In hypothalamic obesity and metabolic hypogonadism, kisspeptin signaling appears altered, raising research interest in metabolic applications. Research routes include subcutaneous bolus (most common), intravenous bolus or infusion, and intranasal formulations under development. Dose ranges depend on the peptide form: kisspeptin-10 boluses at 0.1 to 1.0 nmol/kg for short-duration probes; kisspeptin-54 at 0.3 to 9.6 nmol/kg subcutaneously for triggering or hormonal stimulation studies. Reproductive endocrinology research is the dominant context; smaller programs explore use in sexual desire, mood, and metabolic studies. The development of dual-trigger protocols combining kisspeptin-54 with a GnRH agonist co-trigger has been explored to enhance oocyte maturation rates while preserving the safety advantage over hCG. Pediatric applications, particularly in delayed puberty and disorders of sex development, are an active area of preclinical and early clinical exploration, but no kisspeptin-based therapy has yet received regulatory approval in any jurisdiction. Cross-talk with other neuroendocrine systems (CRH, leptin, ghrelin) creates additional research interest because kisspeptin neurons integrate metabolic, stress, and circadian signals before relaying coordinated input to GnRH neurons, providing an attractive node for therapeutic modulation of the reproductive axis in conditions where multiple upstream perturbations contribute to clinical hypogonadism.
Clinical Trial Efficacy Highlights
- starJayasena, Comninos, Dhillo and colleagues demonstrated that kisspeptin-54 triggers egg maturation in women undergoing IVF with comparable oocyte yields to standard hCG triggers but with dramatically reduced rates of ovarian hyperstimulation syndrome, supporting development as a safer alternative trigger [6].
- starA phase 2 randomized controlled trial showed that a second dose of kisspeptin-54 administered 12 hours after the initial trigger further improved oocyte maturation rates in women at high risk of OHSS, providing dose-response evidence for clinical optimization [7].
- starSkorupskaite and colleagues demonstrated in healthy women that kisspeptin-54 stimulates LH release most potently during the preovulatory phase, with smaller effects in the follicular and luteal phases, mapping the gating role of estradiol on the kisspeptin-GnRH circuit [4].
- starChan, Butler, Dhillo and colleagues showed that kisspeptin-10 boluses in men dose-dependently increase LH pulse frequency from approximately 0.6 to 1.4 pulses per hour and raise serum testosterone, supporting investigation as a male reproductive therapeutic [8].
- starComninos and colleagues demonstrated that kisspeptin-54 administration enhances behavioral and brain responses to sexual and emotional stimuli in healthy men, opening a research line on sexual desire applications distinct from peripheral hormonal effects [9].
- starIn hypothalamic amenorrhea, pulsatile kisspeptin restored LH pulsatility and menstrual cyclicity in early-phase studies, supporting investigation as a treatment for functional hypothalamic amenorrhea unresponsive to lifestyle intervention [10].
- starTwice-daily subcutaneous kisspeptin-54 injection over a menstrual cycle in healthy women did not abolish ovulation or menstrual cyclicity at the doses tested, suggesting that long-acting kisspeptin agonism is feasible without disrupting endogenous cycle dynamics [11].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningAcross published clinical studies in over 1,000 cumulative participants, kisspeptin has been very well tolerated, with no serious adverse events attributable to the peptide and an adverse event profile comparable to placebo.
- warningInjection site reactions including transient erythema, mild discomfort, and pruritus have been described in 5 to 20 percent of subcutaneous administrations, generally resolving within 24 hours.
- warningTransient flushing and mild headache have been reported in approximately 5 to 10 percent of subjects after bolus dosing, consistent with the rapid LH/FSH surge.
- warningIn IVF protocols, the risk of ovarian hyperstimulation syndrome with kisspeptin-54 triggers is dramatically lower than with hCG, but mild and moderate cases have still been reported in women with very high follicle counts.
- warningTheoretical concerns about KISS1R desensitization with continuous dosing have been raised; current protocols generally use intermittent bolus or short-duration infusion to preserve responsiveness.
- warningUse in pregnancy has been studied (kisspeptin levels naturally rise dramatically during pregnancy due to placental expression) and short-term administration appears safe, but it is not approved for therapeutic use during pregnancy.
- warningDrug-drug interactions with conventional reproductive endocrinology agents (clomiphene, letrozole, exogenous gonadotropins) have not been systematically characterized; clinical studies typically wash out other agents before kisspeptin administration.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical kisspeptin dosage?expand_more
Research protocols use kisspeptin-10 boluses at 0.1 to 1.0 nmol/kg subcutaneously or intravenously for short-duration probes, or kisspeptin-54 at 0.3 to 9.6 nmol/kg subcutaneously for sustained stimulation. IVF trigger protocols typically use 9.6 nmol/kg kisspeptin-54 subcutaneously.
How is kisspeptin used in research protocols?expand_more
Primary applications include OHSS-safe trigger for IVF cycles, characterization of GnRH pulse generator function in hypothalamic amenorrhea and hypogonadism, and exploratory work on sexual desire and emotional processing in healthy volunteers. Outcome measures include LH and FSH dynamics, oocyte maturation rates, and validated psychometric scales.
Can kisspeptin be combined with other peptides?expand_more
In IVF research kisspeptin-54 has been combined with GnRH agonist co-triggers in dual-trigger protocols. Combinations with growth hormone secretagogues or other neuropeptides have not been formally evaluated in controlled trials.
What are the side effects of kisspeptin?expand_more
Published clinical experience indicates kisspeptin is very well tolerated, with rates of adverse events similar to placebo. Mild injection site reactions, transient flushing, and mild headache are most common; serious adverse events attributable to the peptide have not been reported.
Is kisspeptin FDA approved?expand_more
No. Kisspeptin-10 and kisspeptin-54 are not approved by the FDA, EMA, or other major regulators. They remain investigational agents under active clinical development, particularly as alternative ovulation triggers in IVF.
Academic References & Study Citations
Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014;20(4):485-500. View Scientific Paper →
Pinilla L, Aguilar E, Dieguez C, Millar RP, Tena-Sempere M. Kisspeptins and reproduction: physiological roles and regulatory mechanisms. Physiol Rev. 2012;92(3):1235-1316. View Scientific Paper →
de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A. 2003;100(19):10972-10976. View Scientific Paper →
Dhillo WS, Chaudhri OB, Thompson EL, et al. Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women. J Clin Endocrinol Metab. 2007;92(10):3958-3966. View Scientific Paper →
Jayasena CN, Comninos AN, Veldhuis JD, et al. A single injection of kisspeptin-54 temporarily increases luteinizing hormone pulsatility in healthy women. Clin Endocrinol (Oxf). 2013;79(4):558-563. View Scientific Paper →
Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-3677. View Scientific Paper →
Abbara A, Clarke S, Islam R, et al. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a phase 2 randomized controlled trial. Hum Reprod. 2017;32(9):1915-1924. View Scientific Paper →
Chan YM, Butler JP, Pinnell NE, et al. Kisspeptin resets the hypothalamic GnRH clock in men. J Clin Endocrinol Metab. 2011;96(8):E1228-E1236. View Scientific Paper →
Comninos AN, Wall MB, Demetriou L, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709-719. View Scientific Paper →
Jayasena CN, Abbara A, Veldhuis JD, et al. Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54. J Clin Endocrinol Metab. 2014;99(6):E953-E961. View Scientific Paper →
Jayasena CN, Abbara A, Narayanaswamy S, et al. Twice-daily subcutaneous injection of kisspeptin-54 does not abolish menstrual cyclicity in healthy female volunteers. J Clin Endocrinol Metab. 2013;98(11):4464-4474. View Scientific Paper →